You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: L2 DIAGNOSTICS LLC Topic: NIAID
DESCRIPTION (provided by applicant): We propose to develop a recombinant subunit vaccine against cutaneous leishmaniasis. This vaccine will incorporate two protein antigens, TSA/TryP and P-4. Both antigens are highly conserved among Leishmania species, arerecognized by T cells of human patients, and confer protection against a live challenge in murine model studies. We expect that immunization usi ...STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
An automated system to differentiate Kawasaki disease from febrile illness with real life clinical datasets in New York CitySBC: HBI SOLUTIONS INC. Topic: 100
ABSTRACT – Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Treatment with intravenous immunoglobulin (IVIG) reduces the incidence of coronary aneurysms and risk of long-term cardiovascular complications. IVIG is recommended to be given within 10 days of illness; however only 4.7% receive the correct diagnosis at the first medical visit. Timely and accurately ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
An automated system to interpret echocardiography to predict adverse outcomes in patients with right ventricular dysfunction in daily hospital practiceSBC: MPROBE, INC. Topic: NHLBI
Project Summary Right ventricle (RV) dysfunction is a common and complex form of pediatric heart disease. It is also a common contributor to morbidity and mortality for patients with congenital heart diseases (CHD). Due to the complex geometry of the RV and its relative adaptability to changing physiologic conditions, RV dysfunction is poorly understood and difficult to characterize precisely and ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: OUI THERAPEUTICS INC Topic: 104
ABSTRACT Suicide is one of the top ten causes of death in the US and suicide rates have increased steadily over the last twenty years. Currently, the most effective treatment options are cognitive behavioral therapies for suicide prevention (CBT-SP), which have been shown to reduce both suicide attempt (SA) risk and suicide ideation (SI). However, access to these treatments is limited because ther ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: OUI THERAPEUTICS INC Topic: 104
ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: IMMUNOBLUE, LLC Topic: NCI
PROJECT SUMMARY Melanoma is one of the most prevalent cancers and is estimated to account for overdeaths inin the United States aloneAlthough highly curable when detected earlytheyear survival rates decline precipitously for patients with regionaland metastaticmelanoma indicating a lack of efficacy of conventional therapiesand a strong need for novel therapies for this patient populationIn respons ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: ADELPHI TECHNOLOGY INC Topic: N/A
DESCRIPTION (provided by applicant): We propose to develop a commercial neutron source for the treatment of brain and liver cancer based on boron neutron capture therapy (BNCT). Boron-containing compounds are injected into a patient's bloodstream and accumulate in a malignant tumor. When irradiated with neutrons, the boron atoms preferentially capture neutrons and decay, releasing short-range radi ...STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
SBC: VLP BIOTECH, INC. Topic: NIAID
DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: CORNOVUS PHARMACEUTICALS INC. Topic: NHLBI
PROJECT SUMMARY Current therapy for ischemic stroke is limited and new treatment is needed since the mortality and morbidity of subjects with this condition remain high. Effort aimed at blocking immune cell- mediated inflammation represents a novel approach. The specific background for the proposed project is that we have identified the myeloid P2X4 receptor (P2X4R), which induces inflammation, as ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulationSBC: REBISCAN, Inc. Topic: N
Project Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health